目的评价替考拉宁治疗重型颅脑损伤合并重度医院感染肺炎的临床疗效及安全性。方法收集重型颅脑损伤合并重度医院感染革兰阳性菌肺炎共43例,应用替考拉宁进行治疗,疗程7~14 d。结果替考拉宁治疗后,患者痊愈31例,显效6例,痊愈率为72.1%,有效率为86.0%;细菌清除38例,清除率为88.4%;不良反应发生2例,发生率为4.7%。结论替考拉宁治疗重型颅脑损伤合并重度医院感染肺炎疗效好,不良反应相对较低,使用较为安全。 Objective To evaluate the clinical efficacy and safety of teicoplanin in the treatment of severe craniocerebral injury with severe nosocomial pneumonia. Methods A total of 43 cases of severe craniocerebral injury with Gram-positive bacterial pneumonia were collected and treated with teicoplanin for 7-14 days. Results Teicoplanin treatment, the patient recovered in 31 cases, 6 cases markedly effective, the cure rate was 72.1%, the effective rate was 86.0%; bacterial clearance 38 cases, the clearance rate was 88.4%; adverse reactions occurred in 2 cases, the incidence was 4.7 %. Conclusion Teicoplanin is effective in treating severe craniocerebral injury with severe nosocomial pneumonia. The adverse reaction is relatively low and safe to use.